The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Light-responsive nanomaterials as nanomedicines: new approaches to treating macular degeneration, cancer and other critical unmet therapeutic needs. Nanotechnology is enabling new medicines for the treatment of important diseases such as cancer and macular degeneration. This project will investigate novel nanomaterials for the development of new highly effective medicines that can be controlled after administration, leading to reduced side effects and increased convenience for patients.
Targeting particulate carriers to epithelial M cells. This project aims to develop and validate an advanced in vitro model of the human intestinal epithelium. The intestine-on-chip model should enable mechanistic studies of the uptake of nano- and micron-size particles by intestinal cells and deliver new insights into the way particulate carriers can be specifically targeted and transported across the intestinal epithelium. Project knowledge and technology are anticipated to generate new commerc ....Targeting particulate carriers to epithelial M cells. This project aims to develop and validate an advanced in vitro model of the human intestinal epithelium. The intestine-on-chip model should enable mechanistic studies of the uptake of nano- and micron-size particles by intestinal cells and deliver new insights into the way particulate carriers can be specifically targeted and transported across the intestinal epithelium. Project knowledge and technology are anticipated to generate new commercialisation opportunities in the oral delivery industry and ultimately, should drive the development of efficient oral formulations for biologics. The model should also reduce the need for animal studies.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100016
Funder
Australian Research Council
Funding Amount
$3,123,492.00
Summary
ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therap ....ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therapeutics. The use of an individual patient’s cellular and molecular research findings will ultimately enable personalised diagnostic and therapeutic decisions.Read moreRead less
Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and h ....Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and hence the risks of dose related side effects. This project has potential both to improve healthcare and to encourage the growth of expertise in the biotechnology industry in Australia.Read moreRead less
Topical peptide delivery for cosmetic and therapeutic benefits. Milk is a major Australian agricultural commodity and is now used in a number of topical products for the management of various skin conditions including chafing in babies, eczema and ageing skin. Hence, this work hopes to contribute to promoting and maintaining good health of Australians.
In addition, there is considerable research being conducted on peptide development for a range of diseases and there may be a possibility of ....Topical peptide delivery for cosmetic and therapeutic benefits. Milk is a major Australian agricultural commodity and is now used in a number of topical products for the management of various skin conditions including chafing in babies, eczema and ageing skin. Hence, this work hopes to contribute to promoting and maintaining good health of Australians.
In addition, there is considerable research being conducted on peptide development for a range of diseases and there may be a possibility of delivering these by the skin.
This work, in seeking to understand some of the fundamental determinants governing how exogenously applied peptides distribute in the skin, is also contributing to the development of Australian pharmaceutical and cosmetic industries.Read moreRead less
Novel click assembled drug-polymer conjugates as next generation drug delivery systems. The purpose of the project is to develop previously inaccessible drug-polymer conjugates with tuneable and sustained drug release rates via a novel polymerisation approach. Ultimately, this will afford next-generation polymer therapeutics suitable for the treatment of a range of disorders and diseases, leading to improvements in heath care.
Engineering Hybrid Materials with Functional Bioactivity in the GI Tract. This project aims to use an advanced particle engineering approach to develop novel biomaterials with multifunctional activities in the gastrointestinal tract. The project expects to generate new fundamental knowledge of the key interfacial processes that control digestion and identify new pathways for modulating gut microbiome composition. By establishing structure-activity relationships through mechanistic in vitro and i ....Engineering Hybrid Materials with Functional Bioactivity in the GI Tract. This project aims to use an advanced particle engineering approach to develop novel biomaterials with multifunctional activities in the gastrointestinal tract. The project expects to generate new fundamental knowledge of the key interfacial processes that control digestion and identify new pathways for modulating gut microbiome composition. By establishing structure-activity relationships through mechanistic in vitro and in vivo models, the knowledge gain will help guide material design for optimised bioactivity. Technology transfer of the lead formulation through quality by design manufacturing practice is anticipated to position the industry partner for future commercial opportunities within the nutraceutical sector.Read moreRead less
Harnessing lipid nano-assembly for next generation functional foods and pharmaceutical products. Nature assembles lipid molecules from our diet into useful structures in our gastrointestinal tract with remarkable precision and versatility. By understanding and harnessing these processes we can design new lipid-based nanomaterials leading to more effective functional foods and pharmaceutical products with reduced side effects.
Physico-chemical and Biopharmaceutical Investigations of Novel Drug Delivery Systems for Oral Administration of Lipophilic Drugs. The new platform technology for carrying lipophilic molecules will be applicable to many molecules currently under development by Australian Industry and will inspire novel encapsulation approaches to new and existing drugs as well as functional foods and nutraceuticals. Improved oral bioavailability of anticancer drugs will improve the quality of life of patients, re ....Physico-chemical and Biopharmaceutical Investigations of Novel Drug Delivery Systems for Oral Administration of Lipophilic Drugs. The new platform technology for carrying lipophilic molecules will be applicable to many molecules currently under development by Australian Industry and will inspire novel encapsulation approaches to new and existing drugs as well as functional foods and nutraceuticals. Improved oral bioavailability of anticancer drugs will improve the quality of life of patients, reduce health care costs and provide broader benefits to the community. The Australian biotechnology/pharmaceutical industries can share in a greater proportion of the US$50 billion market for specialised drug delivery, which is increasing by 20% annually. Australia's scientific competitiveness will be strengthened in the fields of nano-encapsulation and colloidal delivery.Read moreRead less
A Physicochemical Approach for Optimizing Drug Delivery from BioSilicon. By applying modern techniques and a multidisciplinary approach, this research will develop an understanding of drug loading of BioSiliconTM at a molecular level. This novel class of nano-structured biomaterial has exciting potential for developing a range of controllable drug delivery systems. Existing medical applications of BioSilicon deliver only small molecules for very specialised uses. Current research has not focused ....A Physicochemical Approach for Optimizing Drug Delivery from BioSilicon. By applying modern techniques and a multidisciplinary approach, this research will develop an understanding of drug loading of BioSiliconTM at a molecular level. This novel class of nano-structured biomaterial has exciting potential for developing a range of controllable drug delivery systems. Existing medical applications of BioSilicon deliver only small molecules for very specialised uses. Current research has not focused on understanding the pore structure and how it can be adapted for special applications. Our research will create new drug delivery systems with many innovative applications in medical, veterinary and bio-diagnostics fields. The medical and socio-economic impacts will be internationally significant.Read moreRead less